Nav: Home

Patient advocacy groups, industry and individuals join groundbreaking public-private partnership to continue advancing critical Alzheimer's disease research

September 08, 2016

BETHESDA, MD, Sept. 8, 2016 -- The Foundation for the National Institutes of Health (FNIH) announces that patient advocacy groups, private foundations, companies and individual donors have again united in the fight against Alzheimer's disease by donating more than $14 million to launch the third phase of the Alzheimer's Disease Neuroimaging Initiative (ADNI3). Now in its 12th year, this public-private partnership with the National Institutes of Health (NIH) has profoundly influenced the understanding of Alzheimer's disease by identifying and validating biological markers (biomarkers) that signal its onset and progression. Current supporters of ADNI3 are AbbVie, Alzheimer's Association, Bioclinica, Biogen, Cogstate, DiamiR Biosciences, Eisai, Genentech (a member of the Roche Group), Janssen R&D, LLC, Lundbeck, Merck & Company, Inc., PeopleBio, Inc., Pfizer, Inc., Roche, Servier and Takeda. The FNIH anticipates raising a total of $20 million to fund the project.

"More than five million Americans over age 65 are living with Alzheimer's disease today, and that number is set to triple in just over a generation," said Maria Carrillo, Ph.D., Alzheimer's Association Chief Science Officer. "Research is the most powerful weapon in this fight. We've been with ADNI since its inception, brought brain amyloid imaging into the study and the Association is eager to support these breakthrough partnerships. By working together, we can go further, faster, toward our ultimate vision of a world without Alzheimer's disease."

The study is led by the National Institute on Aging (NIA), with support from the FNIH and more than 30 organizations since its launch in 2004. ADNI tracks volunteers at 60 clinical sites in the United States and Canada with normal cognition, mild cognitive impairment and Alzheimer's disease to create a widely-available database of imaging, biochemical and genetic data. Qualified researchers worldwide can quickly access valuable data that lay the groundwork for Alzheimer's discoveries. The extension of ADNI for the next five years will build on the success of its initial phases, confirming the utility of biomarkers that can help improve clinical trial design and support drug development.

"Promoting biomedical research, especially for a complex disease like Alzheimer's, requires the resources and expertise of many partners in both the public and private sectors working together toward a common goal," said Steve Paul M.D., FNIH Chairman. "The FNIH is pleased to continue facilitating the commitments of ADNI partners as we work together to fast-track scientific progress that will eventually lead to effective treatments for this all-to-common and devastating disease."

Additions to the third phase of ADNI include recruiting 1,200 volunteers to join about 800 current participants to enrich the existing dataset, using state-of-the-art imaging techniques to monitor brain levels of tau, a protein that is often abnormal in Alzheimer's patients, and performing cutting-edge analyses to assess complex interactions between the brain and body. ADNI3 also will assess cognitive function through computer tests at home and in the doctor's office and measure changes in subjects' ability to handle money, which can be a warning sign of the disease.

ADNI has already significantly advanced several aspects of Alzheimer's disease research. By standardizing technologies and protocols, it has improved clinical trial design and the understanding of the disease and its progression. Furthermore, ADNI's open-access data policy continues to be a model of successful data sharing in a pre-competitive environment. ADNI data have been downloaded for research purposes more than 11 million times and scientists have used them to publish more than 1,200 scientific papers.

"We are thrilled to embark on this next phase of discovery, enhanced by sophisticated new technologies and computational methods that we could only dream about when we launched the study," said Michael Weiner, M.D., study Principal Investigator, San Francisco Department of Veterans Affairs Medical Center and the University of California, San Francisco. "ADNI has made a profound difference in clinical trials, developing and refining the biomarker tools needed to see Alzheimer's-related brain changes in the living brain--even in people free of symptoms. ADNI3 will play an even more influential role as these biomarkers are enlisted in the search for treatments for this devastating disorder."

The NIH plans to invest an estimated $40 million in ADNI3, in addition to private sector support through the FNIH. Beyond raising funds to support the study, the FNIH coordinates the scientific engagement of private partners, creating a pre-competitive forum where they can participate in study-related scientific exchanges. To learn more about the ADNI3 study and funding opportunities, visit
About the Foundation for the National Institutes of Health

The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world's premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate biomedical research and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1990, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit

Rubenstein Associates, Inc.

Related Brain Articles:

Study describes changes to structural brain networks after radiotherapy for brain tumors
Researchers compared the thickness of brain cortex in patients with brain tumors before and after radiation therapy was applied and found significant dose-dependent changes in the structural properties of cortical neural networks, at both the local and global level.
Blue Brain team discovers a multi-dimensional universe in brain networks
Using a sophisticated type of mathematics in a way that it has never been used before in neuroscience, a team from the Blue Brain Project has uncovered a universe of multi-dimensional geometrical structures and spaces within the networks of the brain.
New brain mapping tool produces higher resolution data during brain surgery
Researchers have developed a new device to map the brain during surgery and distinguish between healthy and diseased tissues.
Newborn baby brain scans will help scientists track brain development
Scientists have today published ground-breaking scans of newborn babies' brains which researchers from all over the world can download and use to study how the human brain develops.
New test may quickly identify mild traumatic brain injury with underlying brain damage
A new test using peripheral vision reaction time could lead to earlier diagnosis and more effective treatment of mild traumatic brain injury, often referred to as a concussion.
This is your brain on God: Spiritual experiences activate brain reward circuits
Religious and spiritual experiences activate the brain reward circuits in much the same way as love, sex, gambling, drugs and music, report researchers at the University of Utah School of Medicine.
Brain scientists at TU Dresden examine brain networks during short-term task learning
'Practice makes perfect' is a common saying. We all have experienced that the initially effortful implementation of novel tasks is becoming rapidly easier and more fluent after only a few repetitions.
Balancing time & space in the brain: New model holds promise for predicting brain dynamics
A team of scientists has extended the balanced network model to provide deep and testable predictions linking brain circuits to brain activity.
New view of brain development: Striking differences between adult and newborn mouse brain
Spikes in neuronal activity in young mice do not spur corresponding boosts in blood flow -- a discovery that stands in stark contrast to the adult mouse brain.
Map of teenage brain provides evidence of link between antisocial behavior and brain development
The brains of teenagers with serious antisocial behavior problems differ significantly in structure to those of their peers, providing the clearest evidence to date that their behavior stems from changes in brain development in early life, according to new research led by the University of Cambridge and the University of Southampton, in collaboration with the University of Rome Tor Vergata in Italy.

Related Brain Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...